74
Participants
Start Date
May 21, 2015
Primary Completion Date
January 31, 2018
Study Completion Date
August 22, 2024
Everolimus
10mg daily by mouth
Tamoxifen
20 mg daily by mouth on alternating weeks (even numbered) weeks
Letrozole
2.5mg once a day by mouth
Medroxyprogesterone Acetate
200 mg daily by mouth
SUNY Downstate Medical Center, Brooklyn
Women's Cancer Care Associates, Albany
Magee Women's Hospital of UPMC, Pittsburgh
The University of Pennsylvania, Philadelphia
Johns Hopkins, Baltimore
Memorial Health University Medical Center, Savannah
John B. Amos Cancer Center, Columbus
University of Miami - Sylvester Comprehensive Cancer Center, Miami
St. Dominic-Jackson Memorial Hospital, Jackson
University of Mississippi Medical Center, Jackson
Ohio State University, Columbus
University Hospital Case Medical Center, Cleveland
Sanford Clinic North - Bemidji, Bemidji
Sanford Medical Center - Sioux Falls, Sioux Falls
Sanford Roger Maris Cancer Center, Fargo
University of Oklahoma, Oklahoma City
University of Texas MD Anderson Cancer Center, Houston
University of Colorado - Anschutz Cancer Pavilion, Aurora
Huntsman Cancer Institute, Salt Lake City
New Mexico Cancer Alliance, Albuquerque
Memorial Medical Center-Cancer Center, Albuquerque
Women's Cancer Center of Nevada, Las Vegas
Maine Medical Center, Scarborough
University of Massachusetts Memorial Center, Worcester
Abington Memorial Hospital, Abington
Women & Infants Hospital of Rhode Island, Providence
Collaborators (1)
Novartis Pharmaceuticals
INDUSTRY
GOG Foundation
NETWORK